NEW YORK (GenomeWeb News) – Meridian Bioscience today said that sales grew 5 percent year over year during its fiscal third quarter as adoption of its molecular diagnostic products continued.

For the three months ended June 30, revenues rose to $42.1 million, up from $40.1, but below the Wall Street consensus of $46.5 million.

Net earnings for the quarter increased to $8.6 million, or $.21 per share, from $6.8 million, or $.17 per share, just shy of analyst estimates of $.22 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.